📊 AMPH Key Takeaways
Is Amphastar Pharmaceuticals, Inc. (AMPH) a Good Investment?
Amphastar faces severe operational deterioration with declining revenue (-1.7% YoY) and collapsing earnings (-33.7% EPS decline), producing abysmal returns on capital (ROE 0.8%, ROA 0.4%). While strong liquidity and positive free cash flow provide near-term financial stability, the pharmaceutical company lacks competitive strength and requires material business improvements to restore shareholder value.
Amphastar Pharmaceuticals shows solid core fundamentals, with healthy profitability, strong free cash flow generation, and very strong liquidity despite a leveraged balance sheet. However, revenue declined slightly year over year, net income was flat, and diluted EPS fell sharply, which points to weaker growth quality and limits conviction until operating momentum improves.
Amphastar Pharmaceuticals, Inc. Key Strengths (AMPH)
- Excellent liquidity position with 3.85x current ratio and 2.82x quick ratio
- Solid free cash flow generation of $38.3M with 22.4% FCF margin
- Adequate cash reserves of $170.9M providing financial flexibility for operations or restructuring
- Strong liquidity profile with 4.02x current ratio and 2.90x quick ratio
- Solid profitability with 49.5% gross margin, 19.5% operating margin, and 13.6% net margin
- Healthy cash generation with $156.12M operating cash flow and $121.23M free cash flow
AMPH Stock Risks: Amphastar Pharmaceuticals, Inc. Investment Risks
- Revenue declining year-over-year (-1.7%) indicating loss of market share or product competitiveness
- Earnings collapsing with 33.7% EPS decline and net income margin compressed to 3.8%
- Interest coverage ratio of 1.6x is critically low with minimal cushion for debt service disruption
- Unacceptable capital returns (ROE 0.8%, ROA 0.4%) demonstrate inefficient capital deployment
- Revenue contraction of 1.7% suggests limited near-term growth momentum
- Diluted EPS declined 33.7% year over year despite flat net income, indicating weaker per-share earnings quality
- Long-term debt of $619.71M and 0.79x debt-to-equity increase balance sheet risk if earnings soften
Key Metrics to Watch
- Quarterly revenue growth rate - need stabilization and return to positive growth
- Operating margin expansion and net margin improvement - currently 8.0% and 3.8% respectively
- Interest coverage ratio trending above 2.0x minimum threshold for sustainable debt service
- Revenue growth and operating income trend
- Diluted EPS trend and long-term debt reduction
Amphastar Pharmaceuticals, Inc. (AMPH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 22.4% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.85x current ratio provides a solid financial cushion.
AMPH Profit Margin, ROE & Profitability Analysis
AMPH vs Healthcare Sector: How Amphastar Pharmaceuticals, Inc. Compares
How Amphastar Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Amphastar Pharmaceuticals, Inc. Stock Overvalued? AMPH Valuation Analysis 2026
Based on fundamental analysis, Amphastar Pharmaceuticals, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Amphastar Pharmaceuticals, Inc. Balance Sheet: AMPH Debt, Cash & Liquidity
AMPH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Amphastar Pharmaceuticals, Inc.'s revenue has grown significantly by 67% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.60 reflects profitable operations.
AMPH Revenue Growth, EPS Growth & YoY Performance
AMPH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $170.5M | $6.4M | $0.14 |
| Q3 2025 | $191.2M | $17.4M | $0.37 |
| Q2 2025 | $174.4M | $25.3M | $0.64 |
| Q1 2025 | $170.5M | $25.3M | $0.51 |
| Q3 2024 | $180.6M | $26.0M | $0.78 |
| Q2 2024 | $145.7M | $26.0M | $0.49 |
| Q1 2024 | $140.0M | $26.0M | $0.50 |
| Q3 2023 | $120.1M | $15.9M | $0.30 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Amphastar Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
AMPH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Amphastar Pharmaceuticals, Inc. (CIK: 0001297184)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Jun 3, 2026 | 4 | xslF345X06/form4-06042026_010605.xml | View → |
| Jun 3, 2026 | 4 | xslF345X06/form4-06042026_010657.xml | View → |
| Jun 3, 2026 | 4 | xslF345X06/form4-06042026_120607.xml | View → |
| Jun 3, 2026 | 4 | xslF345X06/form4-06042026_120654.xml | View → |
| Jun 3, 2026 | 4 | xslF345X06/form4-06042026_120604.xml | View → |
❓ Frequently Asked Questions about AMPH
What is the AI rating for AMPH?
Amphastar Pharmaceuticals, Inc. (AMPH) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AMPH's key strengths?
Claude: Excellent liquidity position with 3.85x current ratio and 2.82x quick ratio. Solid free cash flow generation of $38.3M with 22.4% FCF margin. ChatGPT: Strong liquidity profile with 4.02x current ratio and 2.90x quick ratio. Solid profitability with 49.5% gross margin, 19.5% operating margin, and 13.6% net margin.
What are the risks of investing in AMPH?
Claude: Revenue declining year-over-year (-1.7%) indicating loss of market share or product competitiveness. Earnings collapsing with 33.7% EPS decline and net income margin compressed to 3.8%. ChatGPT: Revenue contraction of 1.7% suggests limited near-term growth momentum. Diluted EPS declined 33.7% year over year despite flat net income, indicating weaker per-share earnings quality.
What is AMPH's revenue and growth?
Amphastar Pharmaceuticals, Inc. reported revenue of $171.2M.
Does AMPH pay dividends?
Amphastar Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find AMPH SEC filings?
Official SEC filings for Amphastar Pharmaceuticals, Inc. (CIK: 0001297184) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AMPH's EPS?
Amphastar Pharmaceuticals, Inc. has a diluted EPS of $0.14.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AMPH's fundamental grade?
Based on our AI fundamental analysis in June 2026, Amphastar Pharmaceuticals, Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AMPH stock overvalued or undervalued?
Valuation metrics for AMPH: ROE of 0.8% (sector avg: 15%), net margin of 3.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AMPH's AI grade for 2026?
Our dual AI analysis gives Amphastar Pharmaceuticals, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AMPH's free cash flow?
Amphastar Pharmaceuticals, Inc.'s operating cash flow is $47.8M, with capital expenditures of $9.5M. FCF margin is 22.4%.
How does AMPH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 3.8% (avg: 12%), ROE 0.8% (avg: 15%), current ratio 3.85 (avg: 2).